The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of equity and acquisition

25 Sep 2009 07:00

RNS Number : 6454Z
Omega Diagnostics Group PLC
25 September 2009
 



25 September 2009 AIM: ODX

Omega Diagnostics Group PLC

("Omega or the "Company")

Issue of Equity and Acquisition

Omega, the AIM listed medical diagnostics company, is today pleased to announce that it has raised £1million before expenses (approximately £884k net of expenses) by way of a conditional placing (the "Placing") of 5,000,000 shares of 4p each in the capital of the Company ("Placing Shares") at 20 pence per share. The Placing was oversubscribed and the Company is pleased to welcome the new institutional investors to the register. The excess demand for Placing Shares has been taken up with the Company's single largest shareholder undertaking to sell his entire stake in the Company to certain of the investors under the Placing.

The proceeds of the Placing will be used partly to fund the acquisition of Co-Tek (South West) Ltd ("Co-Tek"), a company based in Devon which produces various tests for diagnosing bacterial diseases. The business assets comprise plant and machinery, fixtures and fittingsoffice equipment, debtor balances and cash. Net assets immediately prior to the acquisition were approximately £83k. The total consideration for the business and assets is £400k in cash. Omega has raised a further £600k before expenses of working capital which strengthens the balance sheet and provides an ability to react to other opportunities within the diagnostics industry to support further growthManagement expects the transaction to be earnings enhancing in the first full year of trading.

Unaudited financial accounts for the most recently available period covering ten months to 31 July 2009 show that Co-Tek achieved revenue of £188k, gross profit of £169k, EBITDA of £125k and PBT of £119kThe Company also paid a £54k dividend in the period.   Co-Tek has a profitable track record for the past four years.

The acquisition will strengthen Omega's position in the infectious disease test market and provides scope to increase volumes through the use of its broad geographic distribution network in over 100 countries.

David Evans, Chairman of the Company commented:

"We are very pleased with the support received for the Placing from existing and new shareholders for which we give thanks. We also look forward to the positive benefits we can expect from combining Co-Tek's operations with those of the Company including significantly increased channels to market for Co-Tek's products that the acquisition provides."

The Placing is conditional on, inter alia, the Placing Shares being admitted to trading on AIM ("Admission"). Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is expected that admission will occur at 8.00 a.m. on 28 September 2009. The Placing Shares will, when issued, rank pari passu in all respects with the Company's existing ordinary shares. 

After admission of the Placing Shares the figure of 20,632,907 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules. 

For further enquiries please contact

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Nicholas Wells

Andy Roberts

Elizabeth Bowman

Walbrook PR Limited

Tel: 020 7933 8788

Ben Knowles

Paul McManus

Mob: 07900 346978

Ben.knowles@walbrookpr.com

Paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSSNRKNRKUAR
Date   Source Headline
2nd Mar 20217:00 amRNSContract with Screen4
24th Feb 20217:00 amRNSUK-RTC statement on AbC-19TM rapid antibody test
19th Feb 20211:45 pmRNSDirector/PDMR Shareholding
18th Feb 202110:00 amRNSDirector/PDMR Shareholding
16th Feb 20217:00 amRNSAbC-19TM rapid antibody test performance data
15th Feb 20217:00 amRNSDirector/PDMR Shareholding
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:01 amRNSUK Government contract and trading update
11th Feb 20217:00 amRNSDirectorate Change
8th Feb 20219:05 amRNSSecond Price Monitoring Extn
8th Feb 20219:00 amRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSStatement re Media Comment
2nd Feb 20218:45 amRNSExercise of Options and Total Voting Rights
28th Jan 20211:15 pmRNSExercise of Options and Total Voting Rights
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:35 pmRNSPrice Monitoring Extension
26th Jan 20217:02 amRNSLab-based COVID-19 antibody test service launch
26th Jan 20217:01 amRNSUpdate re AbC-19 Rapid Test
25th Jan 202111:06 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
22nd Jan 202110:15 amRNSExercise of Options and Total Voting Rights
22nd Jan 20219:05 amRNSSecond Price Monitoring Extn
22nd Jan 20219:00 amRNSPrice Monitoring Extension
11th Jan 202111:00 amRNSExercise of Options and Total Voting Rights
29th Dec 20207:01 amRNSUpdate re AbC-19 Rapid Test
29th Dec 20207:00 amRNSAbC-19TM Rapid Test Update
24th Dec 202012:41 pmRNSSecond Price Monitoring Extn
24th Dec 202012:35 pmRNSPrice Monitoring Extension
24th Dec 202012:00 pmRNSMologic CE Mark Rapid Antigen Test
24th Dec 202011:05 amRNSSecond Price Monitoring Extn
24th Dec 202011:00 amRNSPrice Monitoring Extension
11th Dec 20202:05 pmRNSSecond Price Monitoring Extn
11th Dec 20202:00 pmRNSPrice Monitoring Extension
11th Dec 20209:45 amRNSExercise of Options and Total Voting Rights
7th Dec 20208:00 amRNSExercise of Options and Total Voting Rights
2nd Dec 20209:00 amRNSDirector/PDMR Shareholding
30th Nov 20202:30 pmRNSExercise of Options and Total Voting Rights
30th Nov 20207:00 amRNSInterim Results
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:01 pmRNSPrice Monitoring Extension
23rd Nov 20209:45 amRNSExercise of Options and Total Voting Rights
17th Nov 20207:45 amRNSUK-RTC Update
16th Nov 20207:16 amRNSHolding(s) in Company
16th Nov 20207:15 amRNSHolding(s) in Company
13th Nov 20202:05 pmRNSSecond Price Monitoring Extn
13th Nov 20202:00 pmRNSPrice Monitoring Extension
13th Nov 20209:30 amRNSExercise of Options and Total Voting Rights
12th Nov 20203:42 pmRNSUK-RTC Statement
12th Nov 202011:05 amRNSSecond Price Monitoring Extn
12th Nov 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.